Valuation: Insulet Corporation

Market Cap 9.66B 8.36B 7.91B 7.16B 13.44B 926B 13.54B 94.39B 36.31B 470B 36.27B 35.47B 1,498B P/E 2026 *
22.7x
P/E 2027 * 18.2x
Enterprise Value 9.71B 8.41B 7.95B 7.2B 13.51B 931B 13.61B 94.88B 36.5B 472B 36.46B 35.65B 1,506B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.49x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week-2.14%
Current month-6.34%
1 month-2.86%
3 months-6.01%
6 months-36.66%
Current year-51.01%
1 week 131.24
Extreme 131.24
140.28
1 month 131.24
Extreme 131.24
155.17
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Director/Board Member 61 2015-07-26
Director/Board Member 54 2020-10-19
Director/Board Member 55 2021-10-17
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Buy

Chief Executive Officer

1,100 0.0016%
8/1/26 Tax

Head of Human Resources

-244 0.0003%
7/1/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-2.14%-59.08%-17.94% 9.56B
-1.03%-3.31%-22.31%+0.29% 178B
-0.05%+1.47%+0.34%+14.65% 120B
-0.90%-0.43%+10.94%+81.33% 62.25B
+0.02%-3.77%+3.09%+38.77% 48.54B
+1.65%+3.81%+0.10%-29.51% 49.82B
+2.09%+2.27%+14.38%-10.28% 31.95B
-1.47%-7.44% - - 28.59B
+2.76%+8.07%+41.73%-7.40% 25B
+1.00%-0.09%-10.10%+4.79% 21.59B
Average +0.52%-1.31%-2.32%+8.30% 57.57B
Weighted average by Cap. -0.06%-1.29%-4.35%+12.25%

Financials

2026 *2027 *
Net sales 3.29B 2.85B 2.69B 2.44B 4.58B 315B 4.61B 32.14B 12.36B 160B 12.35B 12.08B 510B 3.74B 3.24B 3.07B 2.78B 5.21B 359B 5.25B 36.6B 14.08B 182B 14.06B 13.75B 581B
Net income 427M 370M 349M 316M 594M 40.92B 598M 4.17B 1.6B 20.75B 1.6B 1.57B 66.18B 535M 464M 438M 397M 745M 51.35B 751M 5.23B 2.01B 26.04B 2.01B 1.97B 83.04B
Net Debt 49.62M 42.98M 40.64M 36.8M 69.06M 4.76B 69.58M 485M 187M 2.41B 186M 182M 7.7B -322M -279M -264M -239M -449M -30.92B -452M -3.15B -1.21B -15.68B -1.21B -1.18B -50B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-09-15 US$139.24 +1.04% 1,495,883
26-09-14 US$137.80 +4.43% 2,343,552
26-09-11 US$131.96 -2.02% 1,747,977
26-09-10 US$134.68 -2.35% 1,866,957
26-09-09 US$137.92 -3.06% 2,058,782
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
139.24USD
Average target price
171.91USD
Spread / Average Target
+23.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!